Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 77,200 ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against the ...

Ieq Capital LLC bought a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) in the 4th quarter, ...

A young Peninsula drugmaker won regulatory approval Friday for a rare-disease drug picked up in a deal two years ago.

TD Cowen raised the firm’s price target on Travere Therapeutics (TVTX) to $30 from $24 and keeps a Buy rating on the shares. The firm said Q4 ...

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in ...

Travere Therapeutics shares last traded at $22.13, with a volume of 807,056 shares trading hands. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0. ...

Travere Therapeutics (TVTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $1.16 per share a year ago.

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report), with a price ...